RGT Executes Global CannEpil Licensing Deal for US$5.5M
Filed with ASX · · 4 pages · English
Earlier from Argent Biopharma
- Half Yearly Report and Accounts
- Provisional Patent Lodged with USPTO for NanoBodies Platform
- CannEpil - Largest Commercial Shipment Arrives in Ireland
- Quarterly Activities/Appendix 4C Cash Flow Report
- Streamlined Acquisition of AusCann Assets
Later from Argent Biopharma
- CannEpil Global Licence Expands into Veterinary Healthcare
- Notification of cessation of securities - RGT
- US Veterinary Development Programme for CannEpil Commences
- $250,000 in Funding Received under Financing Facility
- Proposed issue of securities - RGT
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma